Le Lézard
Classified in: Science and technology
Subjects: CCA, FVT

Meta to Participate in the Morgan Stanley Technology, Media & Telecom Conference


MENLO PARK, Calif., Feb. 29, 2024 /PRNewswire/ -- Meta, Inc. (NASDAQ: META) today announced that Tom Alison, Head of Facebook, will participate in the Morgan Stanley Technology, Media & Telecom Conference on March 6, 2024 at 11 a.m. Pacific Time. 

A live audio webcast and replay of the fireside chat will be available on Meta's Investor Relations website at: http://investor.fb.com.

Disclosure Information
Meta uses the investor.fb.com and about.fb.com/news/ websites as well as Mark Zuckerberg's Facebook Page (facebook.com/zuck), Instagram account (instagram.com/zuck) and Threads profile (threads.net/zuck) as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. 

About Meta
Meta builds technologies that help people connect, find communities, and grow businesses. When Facebook launched in 2004, it changed the way people connect. Apps like Messenger, Instagram and WhatsApp further empowered billions around the world. Now, Meta is moving beyond 2D screens toward immersive experiences like augmented and virtual reality to help build the next evolution in social technology.

Contacts
Investors:
Kenneth Dorell
[email protected] / investor.fb.com

Press:
Ryan Moore
[email protected] / about.fb.com/news/ 

SOURCE Meta


These press releases may also interest you

at 17:20
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

at 14:15
New Phase 2a Clinical Trial Results Demonstrate Endeavor BioMedicines' ENV-101 Improved Lung Function and Reversed Key Measures of Lung Fibrosis in Patients With Idiopathic Pulmonary Fibrosis
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...

at 12:20
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego,...

at 11:10
Orion Health awarded Panda Health Partner status for its Orchestral Health Intelligence Platform
Orion Health, a global leader in digital health solutions, announced today that it has been awarded partner status by Panda Health for its Orchestral Health Intelligence Platform, one of three pillars of the Unified Healthcare Platform. Panda Health...

at 06:13
eWTP Arabia Capital's Technology Fund I Recognized as Top Performing VC Fund in the Preqin League Tables
eWTP Arabia Capital Technology Fund I ("Techology Fund I"), managed by eWTP Arabia Capital ("eWTPA"), one of the leading private equity firms in the Middle East, was listed in the Preqin League Tables as the the fifth top-performing VC funds in the...

18 mai 2024
Reality TV Star, Mollie Pearce, Backs Campaign to Tackle Inequalities in Condition That Impacts Millions of People Globally
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

More news about Science and technology...


News published on and distributed by: